Title:
IL2 ORTHOLOGS AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2021/146487
Kind Code:
A3
Abstract:
The present disclosure provides orthogonal receptors. In some embodiments, the orthogonal receptor is an orthogonal CD122. In some embodiments, the orthogonal receptor is an orthogonal human CD122 (hCD122). In some embodiments, the orthogonal receptor is an orthogonal CD122 comprising at least one STAT3 binding motifs.
Inventors:
PENAFLOR ASPURIA PAUL-JOSEPH (US)
LUPARDUS PATRICK J (US)
MURPHY RICHARD B (US)
OFT MARTIN (US)
LUPARDUS PATRICK J (US)
MURPHY RICHARD B (US)
OFT MARTIN (US)
Application Number:
PCT/US2021/013521
Publication Date:
August 19, 2021
Filing Date:
January 14, 2021
Export Citation:
Assignee:
SYNTHEKINE INC (US)
International Classes:
A61K48/00; A61K45/00; C07H21/04; C12N5/071; C12N5/16; C12N15/00
Foreign References:
| US20190292533A1 | 2019-09-26 | |||
| US20180228842A1 | 2018-08-16 |
Other References:
UCHIDA ET AL.: "High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral Vector", MOL THE R, vol. 20, no. 10, 2012, pages 1882 - 1892, XP055848239
HOFACRE ET AL.: "Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models", HUM GENE THER, vol. 29, no. 4, 2018, pages 437 - 451, XP055848242
TANG ET AL.: "The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer", CYTOKINE X, vol. 1, no. 1, 10 December 2018 (2018-12-10), XP055636997
ZHAO ET AL.: "Engineered IL -7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer", BIOMED RES INT, vol. 2020, 8 January 2020 (2020-01-08), pages 1 - 13, XP055947925
JOUNAIDI ET AL.: "Tethering IL 2 to Its Receptor IL 2Rb Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells", CANCER RES., vol. 77, no. 21, 2017, pages 5938 - 5951, XP055848247
HOFACRE ET AL.: "Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer Models", HUM GENE THER, vol. 29, no. 4, 2018, pages 437 - 451, XP055848242
TANG ET AL.: "The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer", CYTOKINE X, vol. 1, no. 1, 10 December 2018 (2018-12-10), XP055636997
ZHAO ET AL.: "Engineered IL -7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer", BIOMED RES INT, vol. 2020, 8 January 2020 (2020-01-08), pages 1 - 13, XP055947925
JOUNAIDI ET AL.: "Tethering IL 2 to Its Receptor IL 2Rb Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells", CANCER RES., vol. 77, no. 21, 2017, pages 5938 - 5951, XP055848247
Attorney, Agent or Firm:
HINSCH, Matthew E. et al. (US)
Download PDF: